• 1

    Jemal A, Siegel R, Ward E. Cancer statistics, 2009. CA Cancer J Clin 2009;59:225249.

  • 2

    D’Amato G, Steinert DM, McAuliffe JC, Trent JC. Update on the biology and therapy of gastrointestinal stromal tumors. Cancer Control 2005;12:4456.

    • Search Google Scholar
    • Export Citation
  • 3

    Fletcher CD, Berman JJ, Corless C. Diagnosis of gastrointestinal stromal tumors: a consensus approach. Hum Pathol 2002;33:459465.

  • 4

    Zahm S, Fraumeni JJ. The epidemiology of soft tissue sarcoma. Semin Oncol 1997;24:504514.

  • 5

    Coindre J, Terrier P, Guillou L. Predictive value of grade for metastasis development in the main histologic types of adult soft tissue sarcomas: a study of 1240 patients from the French Federation of Cancer Centers Sarcoma Group. Cancer 2001;91:19141926.

    • Search Google Scholar
    • Export Citation
  • 6

    Cormier JN, Pollock RE. Soft tissue sarcomas. CA Cancer J Clin 2004;54:94109.

  • 7

    Domanski HA. Fine-needle aspiration cytology of soft tissue lesions: diagnostic challenges. Diagn Cytopathol 2007;35:768773.

  • 8

    Antonescu CR. The role of genetic testing in soft tissue sarcoma. Histopathology 2006;48:13–21.

  • 9

    Pfeifer JD, Hill DA, O’Sullivan MJ, Dehner LP. Diagnostic gold standard for soft tissue tumours: morphology or molecular genetics? Histopathology 2000;37:485500.

    • Search Google Scholar
    • Export Citation
  • 10

    Hill DA, O’Sullivan MJ, Zhu X. Practical application of molecular genetic testing as an aid to the surgical pathologic diagnosis of sarcomas: a prospective study. Am J Surg Pathol 2002;26:965977.

    • Search Google Scholar
    • Export Citation
  • 11

    Sorensen PH, Lynch JC, Qualman SJ. PAX3-FKHR and PAX7-FKHR gene fusions are prognostic indicators in alveolar thabdomyosarcoma: a report from the Children’s Oncology Group. J Clin Oncol 2002;20:26722679.

    • Search Google Scholar
    • Export Citation
  • 12

    Guillou L, Benhattar J, Bonichon F. Histologic grade, but not SYT-SSX fusion type, is an important prognostic factor in patients with synovial sarcoma: a multicenter, retrospective analysis. J Clin Oncol 2004;22:40404050.

    • Search Google Scholar
    • Export Citation
  • 13

    Ladanyi M, Antonescu CR, Leung DH. Impact of SYT-SSX fusion type on the clinical behavior of synovial sarcoma: a multi-institutional retrospective study of 243 patients. Cancer Res 2002;62:135140.

    • Search Google Scholar
    • Export Citation
  • 14

    Antonescu CR, Tschernyavsky SJ, Decuseara R. Prognostic impact of P53 status, TLS-CHOP fusion transcript structure, and histological grade in myxoid liposarcoma: a molecular and clinicopathologic study of 82 cases. Clin Cancer Res 2001;7:39773987.

    • Search Google Scholar
    • Export Citation
  • 15

    Guillou L, Coindre J, Bonichon F. Comparative study of the National Cancer Institute and French Federation of Cancer Centers Sarcoma Group grading systems in a population of 410 adult patients with soft tissue sarcoma. J Clin Oncol 1997;15:350362.

    • Search Google Scholar
    • Export Citation
  • 16

    Dileo P, Demetri GD. Update on new diagnostic and therapeutic approaches for sarcomas. Clin Adv Hematol Oncol 2005;3:781791.

  • 17

    Mocellin S, Rossi C, Brandes A, Nitti D. Adult soft tissue sarcomas: conventional therapies and molecularly targeted approaches. Cancer Treat Rev 2006;32:927.

    • Search Google Scholar
    • Export Citation
  • 18

    Brennan MF, Casper ES, Harrison LB. The role of multimodality therapy in soft-tissue sarcoma. Ann Surg 1991;214:328336.

  • 19

    Kim B, Chen YL, Kirsch DG. An effective preoperative three-dimensional radiotherapy target volume for extremity soft tissue sarcoma and the effect of margin width on local control. Int J Radiat Oncol Biol Phys 2010; in press.

    • Search Google Scholar
    • Export Citation
  • 20

    Fleming JB, Berman RS, Cheng SC. Long-term outcome of patients with American Joint Committee on Cancer stage IIB extremity soft tissue sarcomas. J Clin Oncol 1999;17:27722780.

    • Search Google Scholar
    • Export Citation
  • 21

    Gerrand CH, Wunder JS, Kandel RA. Classification of positive margins after resection of soft-tissue sarcoma of the limb predicts the risk of local recurrence. J Bone Joint Surg Br 2001;83:11491155.

    • Search Google Scholar
    • Export Citation
  • 22

    Pisters PW, Leung DH, Woodruff J. Analysis of prognostic factors in 1,041 patients with localized soft tissue sarcomas of the extremities. J Clin Oncol 1996;14:16791689.

    • Search Google Scholar
    • Export Citation
  • 23

    Lewis JJ, Leung D, Espat J. Effect of reresection in extremity soft tissue sarcoma. Ann Surg 2000;231:655663.

  • 24

    Zagars GK, Ballo MT, Pisters PW. Surgical margins and reresection in the management of patients with soft tissue sarcoma using conservative surgery and radiation therapy. Cancer 2003;97:25442553.

    • Search Google Scholar
    • Export Citation
  • 25

    Ghert MA, Abudu A, Driver N. The indications for and the prognostic significance of amputation as the primary surgical procedure for localized soft tissue sarcoma of the extremity. Ann Surg Oncol 2005;12:1017.

    • Search Google Scholar
    • Export Citation
  • 26

    Stojadinovic A, Jaques DP, Leung DH. Amputation for recurrent soft tissue sarcoma of the extremity: indications and outcome. Ann Surg Oncol 2001;8:509518.

    • Search Google Scholar
    • Export Citation
  • 27

    Williard WC, Hajdu SI, Casper ES, Brennan MF. Comparison of amputation with limb-sparing operations for adult soft tissue sarcoma of the extremity. Ann Surg 1992;215:269275.

    • Search Google Scholar
    • Export Citation
  • 28

    DeLaney TF, Trofimov AV, Engelsman M, Suit HD. Advanced-technology radiation therapy in the management of bone and soft tissue sarcomas. Cancer Control 2005;12:2735.

    • Search Google Scholar
    • Export Citation
  • 29

    Leibel SA, Fuks Z, Zelefsky MJ. Intensity-modulated radiotherapy. Cancer J 2002;8:164176.

  • 30

    Davis A, O’Sullivan B, Bell R. Function and health status outcomes in a randomized trial comparing preoperative and postoperative radiotherapy in extremity soft tissue sarcoma. J Clin Oncol 2002;20:44724477.

    • Search Google Scholar
    • Export Citation
  • 31

    Sadoski C, Suit H, Rosenberg A. Preoperative radiation, surgical margins, and local control of extremity sarcomas of soft tissues. J Surg Oncol 1993;52:223230.

    • Search Google Scholar
    • Export Citation
  • 32

    Alektiar KM, Velasco J, Zelefsky MJ. Adjuvant radiotherapy for margin-positive high-grade soft tissue sarcoma of the extremity. Int J Radiat Oncol Biol Phys 2000;48:10511058.

    • Search Google Scholar
    • Export Citation
  • 33

    Cahlon O, Spierer M, Brennan MF. Long-term outcomes in extremity soft tissue sarcoma after a pathologically negative re-resection and without radiotherapy. Cancer 2008;112:27742779.

    • Search Google Scholar
    • Export Citation
  • 34

    Alektiar KM, Leung D, Zelefsky MJ. Adjuvant brachytherapy for primary high-grade soft tissue sarcoma of the extremity. Ann Surg Oncol 2002;9:4856.

    • Search Google Scholar
    • Export Citation
  • 35

    Tran QN, Kim AC, Gottschalk AR. Clinical outcomes of intraoperative radiation therapy for extremity sarcomas. Sarcoma 2006;2006:91671.

  • 36

    Clark MA, Thomas JM. Amputation for soft-tissue sarcoma. Lancet Oncol 2003;4:335342.

  • 37

    Rosenberg SA, Tepper J, Glatstein E. The treatment of soft-tissue sarcomas of the extremities: prospective randomized evaluations of (1) limb-sparing surgery plus radiation therapy compared with amputation and (2) the role of adjuvant chemotherapy. Ann Surg 1982;196:305315.

    • Search Google Scholar
    • Export Citation
  • 38

    Baldini EH, Goldberg J, Jenner C. Long-term outcomes after function-sparing surgery without radiotherapy for soft tissue sarcoma of the extremities and trunk. J Clin Oncol 1999;17:32523259.

    • Search Google Scholar
    • Export Citation
  • 39

    Lin PP, Guzel VB, Pisters PW. Surgical management of soft tissue sarcomas of the hand and foot. Cancer 2002;95:852861.

  • 40

    O’Sullivan B, Davis A, Turcotte R. Five-year results of a randomized phase III trial of pre-operative vs post-operative radiotherapy in extremity soft tissue sarcoma [abstract]. J Clin Oncol 2004;22(Suppl 1):Abstract 9007.

    • Search Google Scholar
    • Export Citation
  • 41

    Yang JC, Chang AE, Baker AR. Randomized prospective study of the benefit of adjuvant radiation therapy in the treatment of soft tissue sarcomas of the extremity. J Clin Oncol 1998;16:197203.

    • Search Google Scholar
    • Export Citation
  • 42

    Wilson AN, Davis A, Bell RS. Local control of soft tissue sarcoma of the extremity: the experience of a multidisciplinary sarcoma group with definitive surgery and radiotherapy. Eur J Cancer 1994;30A:746751.

    • Search Google Scholar
    • Export Citation
  • 43

    Pisters PW, Harrison LB, Leung DH. Long-term results of a prospective randomized trial of adjuvant brachytherapy in soft tissue sarcoma. J Clin Oncol 1996;14:859868.

    • Search Google Scholar
    • Export Citation
  • 44

    Alektiar KM, Brennan MF, Healey JH, Singer S. Impact of intensity-modulated radiation therapy on local control in primary soft-tissue sarcoma of the extremity. J Clin Oncol 2008;26:34403444.

    • Search Google Scholar
    • Export Citation
  • 45

    Kepka L, DeLaney TF, Suit HD, Goldberg SI. Results of radiation therapy for unresected soft-tissue sarcomas. Int J Radiat Oncol Biol Phys 2005;63:852859.

    • Search Google Scholar
    • Export Citation
  • 46

    Clasby R, Tilling K, Smith MA, Fletcher CD. Variable management of soft tissue sarcoma: regional audit with implications for specialist care. Br J Surg 1997;84:16921696.

    • Search Google Scholar
    • Export Citation
  • 47

    Demas BE, Heelan RT, Lane J. Soft-tissue sarcomas of the extremities: comparison of MR and CT in determining the extent of disease. AJR Am J Roentgenol 1988;150:615620.

    • Search Google Scholar
    • Export Citation
  • 48

    Hanna SL, Fletcher BD. MR imaging of malignant soft-tissue tumors. Magn Reson Imaging Clin N Am 1995;3:629650.

  • 49

    Heslin MJ, Smith JK. Imaging of soft tissue sarcomas. Surg Oncol Clin N Am 1999;8:91107.

  • 50

    Schwab JH, Boland P, Guo T. Skeletal metastases in myxoid liposarcoma: an unusual pattern of distant spread. Ann Surg Oncol 2007;14:15071514.

    • Search Google Scholar
    • Export Citation
  • 51

    Schwab JH, Boland PJ, Antonescu C. Spinal metastases from myxoid liposarcoma warrant screening with magnetic resonance imaging. Cancer 2007;110:18151822.

    • Search Google Scholar
    • Export Citation
  • 52

    Tateishi U, Hasegawa T, Beppu Y. Prognostic significance of MRI findings in patients with myxoid-round cell liposarcoma. AJR Am J Roentgenol 2004;182:725731.

    • Search Google Scholar
    • Export Citation
  • 53

    Portera CA Jr, Ho V, Patel SR. Alveolar soft part sarcoma: clinical course and patterns of metastasis in 70 patients treated at a single institution. Cancer 2001;91:585591.

    • Search Google Scholar
    • Export Citation
  • 54

    Schuetze SM. Utility of positron emission tomography in sarcomas. Curr Opin Oncol 2006;18:369373.

  • 55

    Folpe AL, Lyles RH, Sprouse JT. (F-18) fluorodeoxyglucose positron emission tomography as a predictor of pathologic grade and other prognostic variables in bone and soft tissue sarcoma. Clin Cancer Res 2000;6:12791287.

    • Search Google Scholar
    • Export Citation
  • 56

    Schuetze SM, Rubin BP, Vernon C. Use of positron emission tomography in localized extremity soft tissue sarcoma treated with neoadjuvant chemotherapy. Cancer 2005;103:339348.

    • Search Google Scholar
    • Export Citation
  • 57

    Eary JF, O’Sullivan F, Powitan Y. Sarcoma tumor FDG uptake measured by PET and patient outcome: a retrospective analysis. Eur J Nucl Med Mol Imaging 2002;29:11491154.

    • Search Google Scholar
    • Export Citation
  • 58

    Geer RJ, Woodruff J, Casper ES, Brennan MF. Management of small soft-tissue sarcoma of the extremity in adults. Arch Surg 1992;127:12851289.

  • 59

    Karakousis CP, Emrich LJ, Rao U, Khalil M. Limb salvage in soft tissue sarcomas with selective combination of modalities. Eur J Surg Oncol 1991;17:7180.

    • Search Google Scholar
    • Export Citation
  • 60

    Pisters PW, O’Sullivan B, Maki RG. Evidence-based recommendations for local therapy for soft tissue sarcomas. J Clin Oncol 2007;25:10031008.

    • Search Google Scholar
    • Export Citation
  • 61

    Pisters PW, Pollock RE, Lewis VO. Long-term results of prospective trial of surgery alone with selective use of radiation for patients with T1 extremity and trunk soft tissue sarcomas. Ann Surg 2007;246:675681; discussion 681–682.

    • Search Google Scholar
    • Export Citation
  • 62

    Kraybill WG, Harris J, Spiro IJ. Phase II study of neoadjuvant chemotherapy and radiation therapy in the management of high-risk, high-grade, soft tissue sarcomas of the extremities and body wall: Radiation Therapy Oncology Group trial 9514. J Clin Oncol 2006;24:619625.

    • Search Google Scholar
    • Export Citation
  • 63

    Grobmyer SR, Maki RG, Demetri GD. Neo-adjuvant chemotherapy for primary high-grade extremity soft tissue sarcoma. Ann Oncol 2004;15:16671672.

    • Search Google Scholar
    • Export Citation
  • 64

    DeLaney TF SI, Suit HD, Gebhardt MC. Neoadjuvant chemotherapy and radiotherapy for large extremity soft-tissue sarcomas. Int J Radiat Oncol Biol Phys 2003;56:11171127.

    • Search Google Scholar
    • Export Citation
  • 65

    Pisters PW, Patel SR, Varma DG. Preoperative chemotherapy for stage IIIB extremity soft tissue sarcoma: long-term results from a single institution. J Clin Oncol 1997;15:34813487.

    • Search Google Scholar
    • Export Citation
  • 66

    Pisters PW, Ballo MT, Patel SR. Preoperative chemoradiation treatment strategies for localized sarcoma. Ann Surg Oncol 2002;9:535542.

  • 67

    Maki RG. Role of chemotherapy in patients with soft tissue sarcomas. Expert Rev Anticancer Ther 2004;4:229236.

  • 68

    Tierney JF, Mosseri V, Stewart LA. Adjuvant chemotherapy for soft-tissue sarcoma: review and meta-analysis of the published results of randomised clinical trials. Br J Cancer 1995;72:469475.

    • Search Google Scholar
    • Export Citation
  • 69

    Adjuvant chemotherapy for localised resectable soft-tissue sarcoma of adults: meta-analysis of individual data. Sarcoma Meta-analysis Collaboration. Lancet 1997;350:16471654.

    • Search Google Scholar
    • Export Citation
  • 70

    Bramwell V, Rouesse J, Steward W. Adjuvant CYVADIC chemotherapy for adult soft tissue sarcoma—reduced local recurrence but no improvement in survival: a study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. J Clin Oncol 1994;12:11371149.

    • Search Google Scholar
    • Export Citation
  • 71

    Cormier JN, Huang X, Xing Y. Cohort analysis of patients with localized, high-risk, extremity soft tissue sarcoma treated at two cancer centers: chemotherapy-associated outcomes. J Clin Oncol 2004;22:45674574.

    • Search Google Scholar
    • Export Citation
  • 72

    Frustaci S, De Paoli A, Bidoli E. Ifosfamide in the adjuvant therapy of soft tissue sarcomas. Oncology 2003;65:8084.

  • 73

    Frustaci S, Gherlinzoni F, De Paoli A. Adjuvant chemotherapy for adult soft tissue sarcomas of the extremities and girdles: results of the Italian randomized cooperative trial. J Clin Oncol 2001;19:12381247.

    • Search Google Scholar
    • Export Citation
  • 74

    Woll PJ, van Glabbeke M, Hohenberger P. Adjuvant chemotherapy (CT) with doxorubicin and ifosfamide in resected soft tissue sarcoma (STS): interim analysis of a randomised phase III trial [abstract]. J Clin Oncol 2007;25(Suppl 1):Abstract 10008.

    • Search Google Scholar
    • Export Citation
  • 75

    Alektiar KM, Leung D, Zelefsky MJ, Brennan MF. Adjuvant radiation for stage II-B soft tissue sarcoma of the extremity. J Clin Oncol 2002;20:16431650.

    • Search Google Scholar
    • Export Citation
  • 76

    Antman K, Crowley J, Balcerzak S. An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas. J Clin Oncol 1993;11:12761285.

    • Search Google Scholar
    • Export Citation
  • 77

    Antman KH, Judson EA. Dana-Farber Cancer Institute studies in advanced sarcoma. Semin Oncol 1990;1:715.

  • 78

    Bramwell VH, Anderson D, Charette ML. Doxorubicin-based chemotherapy for the palliative treatment of adult patients with locally advanced or metastatic soft tissue sarcoma. Cochrane Database Syst Rev 2003;CD003293.

    • Search Google Scholar
    • Export Citation
  • 79

    Edmonson J, Ryan L, Blum R. Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas. J Clin Oncol 1993;11:12691275.

    • Search Google Scholar
    • Export Citation
  • 80

    Elias A, Ryan L, Sulkes A. Response to mesna, doxorubicin, ifosfamide, and dacarbazine in 108 patients with metastatic or unresectable sarcoma and no prior chemotherapy. J Clin Oncol 1989;7:12081216.

    • Search Google Scholar
    • Export Citation
  • 81

    Lorigan P, Verweij J, Papai Z. Phase III trial of two investigational schedules of ifosfamide compared with standard-dose doxorubicin in advanced or metastatic soft tissue sarcoma: a European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study. J Clin Oncol 2007;25:31443150.

    • Search Google Scholar
    • Export Citation
  • 82

    Santoro A, Tursz T, Mouridsen H. Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. J Clin Oncol 1995;13:15371545.

    • Search Google Scholar
    • Export Citation
  • 83

    Zalupski M, Metch B, Balcerzak S. Phase III comparison of doxorubicin and dacarbazine given by bolus versus infusion in patients with soft-tissue sarcomas: a Southwest Oncology Group study. J Natl Cancer Inst 1991;83:926932.

    • Search Google Scholar
    • Export Citation
  • 84

    Siehl JM, Thiel E, Schmittel A. Liposomal anthracyclines and ifosfamide in the first line treatment of advanced soft tissue sarcomas: a two cohort phase II study [abstract]. J Clin Oncol 2006;24(Suppl 1):Abstract 9563.

    • Search Google Scholar
    • Export Citation
  • 85

    Siehl JM, Thiel E, Schmittel A. Ifosfamide/liposomal daunorubicin is a well tolerated and active first-line chemotherapy regimen in advanced soft tissue sarcoma: results of a phase II study. Cancer 2005;104:611617.

    • Search Google Scholar
    • Export Citation
  • 86

    Hensley ML, Maki R, Venkatraman E. Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial. J Clin Oncol 2002;20:28242831.

    • Search Google Scholar
    • Export Citation
  • 87

    Maki RG, Wathen JK, Patel SR. Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002. J Clin Oncol 2007;25:27552763.

    • Search Google Scholar
    • Export Citation
  • 88

    Leu KM, Ostruszka LJ, Shewach D. Laboratory and clinical evidence of synergistic cytotoxicity of sequential treament with gemcitabine followed by docetaxel in the treatment of sarcoma. J Clin Oncol 2004;22:17061712.

    • Search Google Scholar
    • Export Citation
  • 89

    Bay JO, Ray-Coquard I, Fayette J. Docetaxel and gemcitabine combination in 133 advanced soft-tissue sarcomas: a retrospective analysis. Int J Cancer 2006;119:706711.

    • Search Google Scholar
    • Export Citation
  • 90

    Dileo P, Morgan JA, Zahrieh D. Gemcitabine and vinorelbine combination chemotherapy for patients with advanced soft tissue sarcomas: results of a phase II trial. Cancer 2007;109:18631869.

    • Search Google Scholar
    • Export Citation
  • 91

    Garcia del Muro X, Lopez-Pousa A, Martin J. A phase II trial of temozolomide as a 6-week, continuous, oral schedule in patients with advanced soft tissue sarcoma: a study by the Spanish Group for Research on Sarcomas. Cancer 2005;104:17061712.

    • Search Google Scholar
    • Export Citation
  • 92

    Talbot SM, Keohan ML, Hesdorffer M. A phase II trial of temozolomide in patients with unresectable or metastatic soft tissue sarcoma. Cancer 2003;98:19421946.

    • Search Google Scholar
    • Export Citation
  • 93

    Le Cesne A, Blay JY, Judson I. Phase II study of ET-743 in advanced soft tissue sarcomas: a European Organisation for the Research and Treatment of Cancer (EORTC) Soft Tissue and Bone Sarcoma Group trial. J Clin Oncol 2005;23:576584.

    • Search Google Scholar
    • Export Citation
  • 94

    Garcia-Carbonero R, Supko JG, Manola J. Phase II and pharmacokinetic study of ecteinascidin 743 in patients with progressive sarcomas of soft tissues refractory to chemotherapy. J Clin Oncol 2004;22:14801490.

    • Search Google Scholar
    • Export Citation
  • 95

    Garcia-Carbonero R, Supko JG, Maki RG. Ecteinascidin-743 (ET-743) for chemotherapy-naive patients with advanced soft tissue sarcomas: multicenter phase II and pharmacokinetic study. J Clin Oncol 2005;23:54845492.

    • Search Google Scholar
    • Export Citation
  • 96

    Yovine A, Riofrio M, Blay JY. Phase II study of ecteinascidin-743 in advanced pretreated soft tissue sarcoma patients. J Clin Oncol 2004;22:890899.

    • Search Google Scholar
    • Export Citation
  • 97

    Laverdiere C, Kolb EA, Supko JG. Phase II study of ecteinascidin 743 in heavily pretreated patients with recurrent osteosarcoma. Cancer 2003;98:832840.

    • Search Google Scholar
    • Export Citation
  • 98

    Issels RD, Lindner LH, Wust P. Regional hyperthermia (RHT) improves response and survival when combined with systemic chemotherapy in the management of locally advanced, high grade soft tissue sarcomas (STS) of the extremities, the body wall and the abdomen: a phase III randomised pros [abstract]. J Clin Oncol 2007;25(Suppl 1):Abstract 10009.

    • Search Google Scholar
    • Export Citation
  • 99

    Issels R, Schlemmer M. Current trials and new aspects in soft tissue sarcoma of adults. Cancer Chemother Pharmacol 2002;49(Suppl 1):S48.

  • 100

    Grunhagen DJ, Brunstein F, ten Hagen TL. TNF-based isolated limb perfusion: a decade of experience with antivascular therapy in the management of locally advanced extremity soft tissue sarcomas. Cancer Treat Res 2004;120:6579.

    • Search Google Scholar
    • Export Citation
  • 101

    Grunhagen DJ, de Wilt JH, Graveland WJ. Outcome and prognostic factor analysis of 217 consecutive isolated limb perfusions with tumor necrosis factor-alpha and melphalan for limb-threatening soft tissue sarcoma. Cancer 2006;106:17761784.

    • Search Google Scholar
    • Export Citation
  • 102

    Whooley BP, Mooney MM, Gibbs JF, Kraybill WG. Effective follow-up strategies in soft tissue sarcoma. Semin Surg Oncol 1999;17:8387.

  • 103

    Whooley BP, Gibbs JF, Mooney MM. Primary extremity sarcoma: what is the appropriate follow-up? Ann Surg Oncol 2000;7:914.

  • 104

    Kane JM III. Surveillance strategies for patients following surgical resection of soft tissue sarcomas. Curr Opin Oncol 2004;16:328332.

    • Search Google Scholar
    • Export Citation
  • 105

    Lewis JJ, Leung D, Casper ES. Multifactorial analysis of long-term follow-up (more than 5 years) of primary extremity sarcoma. Arch Surg 1999;134:190194.

    • Search Google Scholar
    • Export Citation
  • 106

    Fleming JB, Cantor SB, Varma DG. Utility of chest computed tomography for staging in patients with T1 extremity soft tissue sarcomas. Cancer 2001;92:863868.

    • Search Google Scholar
    • Export Citation
  • 107

    Singer S, Antman K, Corson JM, Eberlein TJ. Long-term salvageability for patients with locally recurrent soft-tissue sarcomas. Arch Surg 1992;127:548553; discussion 553–544. References 108–127 are cited in the section on “Retroperitoneal/Intra-Abdominal Soft Tissue Sarcomas,” and are available in the version of these guidelines online at www.NCCN. org.

    • Search Google Scholar
    • Export Citation
  • 128

    Hirota S, Isozaki K, Moriyama Y. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 1998;279:577580.

  • 129

    Heinrich MC, Corless CL, Duensing A. PDGFRA activating mutations in gastrointestinal stromal tumors. Science 2003;299:708710.

  • 130

    Hirota S, Ohashi A, Nishida T. Gain-of-function mutations of platelet-derived growth factor receptor alpha gene in gastrointestinal stromal tumors. Gastroenterology 2003;125:660667.

    • Search Google Scholar
    • Export Citation
  • 131

    Miettinen M, Lasota J. Gastrointestinal stromal tumors: pathology and prognosis at different sites. Semin Diagn Pathol 2006;23:7083.

  • 132

    Miettinen M, Lasota J. Gastrointestinal stromal tumors: review on morphology, molecular pathology, prognosis, and differential diagnosis. Arch Pathol Lab Med 2006;130:14661478.

    • Search Google Scholar
    • Export Citation
  • 133

    Demetri GD, von Mehren M, Blanke CD. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002;347:472480.

    • Search Google Scholar
    • Export Citation
  • 134

    Blanke CD, Demetri GD, von Mehren M. Long-term results from a randomized phase II trial of standard-versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. J Clin Oncol 2008;26:620625.

    • Search Google Scholar
    • Export Citation
  • 135

    Verweij J, Casali PG, Zalcberg J. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet 2004;364:11271134.

    • Search Google Scholar
    • Export Citation
  • 136

    Blanke CD, Rankin C, Demetri GD. Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. J Clin Oncol 2008;26:626632.

    • Search Google Scholar
    • Export Citation
  • 137

    Dagher R, Cohen M, Williams G. Approval summary: imatinib mesylate in the treatment of metastatic and/or unresectable malignant gastrointestinal stromal tumors. Clin Cancer Res 2002;8:30343038.

    • Search Google Scholar
    • Export Citation
  • 138

    Lasota J, Miettinen M. Clinical significance of oncogenic KIT and PDGFRA mutations in gastrointestinal stromal tumours. Histopathology 2008;53:245266.

    • Search Google Scholar
    • Export Citation
  • 139

    Heinrich MC, Corless CL, Demetri GD. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 2003;21:43424349.

    • Search Google Scholar
    • Export Citation
  • 140

    Debiec-Rychter M, Dumez H, Judson I. Use of c-KIT/PDGFRA mutational analysis to predict the clinical response to imatinib in patients with advanced gastrointestinal stromal tumours entered on phase I and II studies of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer 2004;40:689695.

    • Search Google Scholar
    • Export Citation
  • 141

    Heinrich MC, Owzar K, Corless CL. Correlation of kinase genotype and clinical outcome in the North American Intergroup phase III trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group. J Clin Oncol 2008;26:53605367.

    • Search Google Scholar
    • Export Citation
  • 142

    Zalcberg JR, Verweij J, Casali PG. Outcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily imatinib dose of 800 mg after progression on 400 mg. Eur J Cancer 2005;41:17511757.

    • Search Google Scholar
    • Export Citation
  • 143

    Debiec-Rychter M, Sciot R, Le Cesne A. KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours. Eur J Cancer 2006;42:10931103.

    • Search Google Scholar
    • Export Citation
  • 144

    Gastrointestinal stromal tumor meta-analysis group comparison of two doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors: a meta-analysis of 1,640 Patients. J Clin Oncol 2010;28:12471253.

    • Search Google Scholar
    • Export Citation
  • 145

    Eisenberg BL, Harris J, Blanke CD. Phase II trial of neoadjuvant/adjuvant imatinib mesylate (IM) for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumor (GIST): early results of RTOG 0132/ACRIN 6665. J Surg Oncol 2009;99:4247.

    • Search Google Scholar
    • Export Citation
  • 146

    McAuliffe JC, Hunt KK, Lazar AJ. A randomized, phase II study of preoperative plus postoperative imatinib in GIST: evidence of rapid radiographic response and temporal induction of tumor cell apoptosis. Ann Surg Oncol 2009;16:910919.

    • Search Google Scholar
    • Export Citation
  • 147

    Eisenberg BL, Judson I. Surgery and imatinib in the management of GIST: emerging approaches to adjuvant and neoadjuvant therapy. Ann Surg Oncol 2004;11:465475.

    • Search Google Scholar
    • Export Citation
  • 148

    Gold JS, Dematteo RP. Combined surgical and molecular therapy: the gastrointestinal stromal tumor model. Ann Surg 2006;244:176184.

  • 149

    DeMatteo RP, Lewis JJ, Leung D. Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann Surg 2000;231:5158.

    • Search Google Scholar
    • Export Citation
  • 150

    Dematteo RP, Antonescu CR, Chadaram V. Adjuvant imatinib mesylate in patients with primary high risk gastrointestinal stromal tumor (GIST) following complete resection: safety results from the U.S. Intergroup phase II trial ACOSOG Z9000 [abstract]. J Clin Oncol 2005;23(Suppl 1):Abstract 9009.

    • Search Google Scholar
    • Export Citation
  • 151

    Dematteo RP, Ballman KV, Antonescu CR. Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial. Lancet 2009;373:10971104.

    • Search Google Scholar
    • Export Citation
  • 152

    Guilhot F. Indications for imatinib mesylate therapy and clinical management. Oncologist 2004;9:271281.

  • 153

    Trent JC, Patel SS, Zhang J. Rare incidence of congestive heart failure in gastrointestinal stromal tumor and other sarcoma patients receiving imatinib mesylate. Cancer 2010;116:184192.

    • Search Google Scholar
    • Export Citation
  • 154

    Benjamin RS, Debiec-Rychter M, Le Cesne A. Gastrointestinal stromal tumors II: medical oncology and tumor response assessment. Semin Oncol 2009;36:302311.

    • Search Google Scholar
    • Export Citation
  • 155

    Maleddu A, Pantaleo MA, Nannini M. Mechanisms of secondary resistance to tyrosine kinase inhibitors in gastrointestinal stromal tumours (review). Oncol Rep 2009;21:13591366.

    • Search Google Scholar
    • Export Citation
  • 156

    Heinrich MC, McArthur GA, Demetri GD. Clinical and molecular studies of the effect of imatinib on advanced aggressive fibromatosis (desmoid tumor). J Clin Oncol 2006;24:11951203.

    • Search Google Scholar
    • Export Citation
  • 157

    Demetri GD, van Oosterom AT, Garrett CR. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 2006;368:13291338.

    • Search Google Scholar
    • Export Citation
  • 158

    George S, Blay JY, Casali PG. Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure. Eur J Cancer 2009;45:19591968.

    • Search Google Scholar
    • Export Citation
  • 159

    Chu D, Lacouture ME, Weiner E, Wu S. Risk of hand-foot skin reaction with the multitargeted kinase inhibitor sunitinib in patients with renal cell and non-renal cell carcinoma: a meta-analysis. Clin Genitourin Cancer 2009;7:1119.

    • Search Google Scholar
    • Export Citation
  • 160

    Zhu X, Stergiopoulos K, Wu S. Risk of hypertension and renal dysfunction with an angiogenesis inhibitor sunitinib: systematic review and meta-analysis. Acta Oncol 2009;48:917.

    • Search Google Scholar
    • Export Citation
  • 161

    Chu TF, Rupnick MA, Kerkela R. Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet 2007;370:20112019.

  • 162

    Torino F, Corsello SM, Longo R. Hypothyroidism related to tyrosine kinase inhibitors: an emerging toxic effect of targeted therapy. Nat Rev Clin Oncol 2009;6:219228.

    • Search Google Scholar
    • Export Citation
  • 163

    Sepe PS, Moparty B, Pitman MB. EUS-guided FNA for the diagnosis of GI stromal cell tumors: sensitivity and cytologic yield. Gastrointest Endosc 2009;70:254261.

    • Search Google Scholar
    • Export Citation
  • 164

    Van den Abbeele AD. The lessons of GIST—PET and PET/CT: a new paradigm for imaging. Oncologist 2008;13(Suppl 2):813.

  • 165

    Van Den Abbeele AD, Badawi RD, Manola J. Effects of cessation of imatinib mesylate (IM) therapy in patients (pts) with IM-refractory gastrointestinal stromal tumors (GIST) as visualized by FDG-PET scanning [abstract]. J Clin Oncol 2004;22(Suppl 1):Abstract 3012.

    • Search Google Scholar
    • Export Citation
  • 166

    Blay JY, Le Cesne A, Ray-Coquard I. Prospective multicentric randomized phase III study of imatinib in patients with advanced gastrointestinal stromal tumors comparing interruption versus continuation of treatment beyond 1 year: the French Sarcoma Group. J Clin Oncol 2007;25:11071113.

    • Search Google Scholar
    • Export Citation
  • 167

    Dematteo RP, Gold JS, Saran L. Tumor mitotic rate, size, and location independently predict recurrence after resection of primary gastrointestinal stromal tumor (GIST). Cancer 2008;112:608615.

    • Search Google Scholar
    • Export Citation
  • 168

    Gold JS, Gonen M, Gutierrez A. Development and validation of a prognostic nomogram for recurrence-free survival after complete surgical resection of localised primary gastrointestinal stromal tumour: a retrospective analysis. Lancet Oncol 2009;10:10451052.

    • Search Google Scholar
    • Export Citation
  • 169

    Raut CP, Posner M, Desai J. Surgical management of advanced gastrointestinal stromal tumors after treatment with targeted systemic therapy using kinase inhibitors. J Clin Oncol 2006;24:23252331.

    • Search Google Scholar
    • Export Citation
  • 170

    Wiebe L, Kasza KE, Maki RG. Activity of sorafenib (SOR) in patients (pts) with imatinib (IM) and sunitinib (SU)-resistant (RES) gastrointestinal stromal tumors (GIST): a phase II trial of the University of Chicago Phase II Consortium [abstract]. J Clin Oncol 2008;26(Suppl 1):Abstract 10502.

    • Search Google Scholar
    • Export Citation
  • 171

    Blay JY, Casali PG, Reichardt P. A phase I study of nilotinib alone and in combination with imatinib in patients with imatinib-resistant gastrointestinal stromal tumors (GIST): study update [abstract]. J Clin Oncol 2008;26(Suppl 1):Abstract 10553.

    • Search Google Scholar
    • Export Citation
  • 172

    Demetri GD, Lo Russo P, MacPherson IR. Phase I dose-escalation and pharmacokinetic study of dasatinib in patients with advanced solid tumors. Clin Cancer Res 2009;15:62326240.

    • Search Google Scholar
    • Export Citation
  • 173

    Fumagalli E, Coco P, Morosi C. Rechallenge with imatinib in GIST patients resistant to second or third line therapy. Presented at the 2009 Connective Tissue Oncology Society 15th Annual Meeting; November 5–7, 2009; Miami Beach, Florida. Abstract 39404. References 174–201 are cited in the section on “Desmoid Tumors (Fibromatoses),” and are available in the version of these guidelines online at www.NCCN.org.

    • Search Google Scholar
    • Export Citation
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 803 516 29
PDF Downloads 97 73 5
EPUB Downloads 0 0 0